Skip to main content
Livermore
Livermore
ZHEN

Royce & Associates LP

SEC CIK
0000906304
Latest filing
Aug 14, 2026

CPRX holding history

Catalyst Pharmaceuticals, Inc. in every 13F filed by Royce & Associates LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CPRX overviewAll 13F holders of CPRXFull Q2 2026 holdings

Shares (Q2 2026)
358,642
Value
$11.3M
% of portfolio
0.1%
Quarters held
22
Since Q1 2021
Holdings of CPRX by Royce & Associates LP, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026358,642$11.3M0.1%−1,731,264−82.8%ReducedHolders
Q1 20262,089,906$51.7M0.5%+179,139+9.4%AddedHolders
Q4 20251,910,767$44.6M0.5%−124,198−6.1%ReducedHolders
Q3 20252,034,965$40.1M0.4%+452,103+28.6%AddedHolders
Q2 20251,582,862$34.3M0.4%−15,498−1.0%ReducedHolders
Q1 20251,598,360$38.8M0.4%−265,991−14.3%ReducedHolders
Q4 20241,864,351$38.9M0.4%−156,754−7.8%ReducedHolders
Q3 20242,021,105$40.2M0.4%−140,917−6.5%ReducedHolders
Q2 20242,162,022$33.5M0.3%+78,009+3.7%AddedHolders
Q1 20242,084,013$33.2M0.3%+340,939+19.6%AddedHolders
Q4 20231,743,074$29.3M0.3%+131,372+8.2%AddedHolders
Q3 20231,611,702$18.8M0.2%+571,714+55.0%AddedHolders
Q2 20231,039,988$14.0M0.1%+424,020+68.8%AddedHolders
Q1 2023615,968$10.2M0.1%+84,079+15.8%AddedHolders
Q4 2022531,889$9.89M0.1%−126,658−19.2%ReducedHolders
Q3 2022658,547$8.45M0.1%−1,441,678−68.6%ReducedHolders
Q2 20222,100,225$14.7M0.2%−161,682−7.1%ReducedHolders
Q1 20222,261,907$18.8M0.2%−321,961−12.5%ReducedHolders
Q4 20212,583,868$17.5M0.1%−423,126−14.1%ReducedHolders
Q3 20213,006,994$15.9M0.1%−66,852−2.2%ReducedHolders
Q2 20213,073,846$17.7M0.1%−175,804−5.4%ReducedHolders
Q1 20213,249,650$15.0M0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.